The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onset

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Volumn 17, Issue 5-6, 2016, Pages 414-425

  Proudfoot, Malcolm ^a   Jones, Ashley ^b   Talbot, Kevin ^a   Al Chalabi, Ammar ^b   Turner, Martin R ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

clinical trial; modelling; Motor neuron disease; prognosis; survival

Indexed keywords

AMYOTROPHIC LATERAL SCLEROSIS; AMYOTROPHIC LATERAL SCLEROSIS FUNCTIONAL RATING SCORE; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DISEASE COURSE; DISEASE DURATION; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MORTALITY RISK; NEUROLOGIC DISEASE ASSESSMENT; PRIORITY JOURNAL; RESPIRATORY FUNCTION; SURVIVAL; SURVIVOR; FEMALE; MALE; MORTALITY; OUTCOME ASSESSMENT; REPRODUCIBILITY; SEVERITY OF ILLNESS INDEX; TIME FACTOR;

AMYOTROPHIC LATERAL SCLEROSIS; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; OUTCOME ASSESSMENT (HEALTH CARE); REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84958049282     PISSN: 21678421     EISSN: 21679223     Source Type: Journal    
DOI: 10.3109/21678421.2016.1140786     Document Type: Article

References (51)

1. M.R.Turner, O.Hardiman, M.Benatar, B.R.Brooks, A.Chio, M.de Carvalho, et al. Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol. 2013;12:310–22.
2. C.K.Jablecki, C.Berry, J.Leach Survival prediction in amyotrophic lateral sclerosis. Muscle Nerve. 1989;12: 833–41.
3. T.Kihira, S.Yoshida, K.Okamoto, Y.Kazimoto, M.Ookawa, K.Hama, et al. Survival rate of patients with amyotrophic lateral sclerosis in Wakayama Prefecture, Japan, 1966 to 2005. J Neurol Sci. 2008;268:95–101.
4. E.Pupillo, P.Messina, G.Logroscino, E.Beghi Long-term survival in amyotrophic lateral sclerosis: a population based study. Ann Neurol. 2014;75:287–97.
5. P.Kaufmann, G.Levy, J.L.P.Thompson, M.L.Delbene, V.Battista, P.H.Gordon, et al. The ALSFRS-R predicts survival time in an ALS clinic population. Neurology. 2005;64:38–43.
6. H.Watanabe, N.Atsuta, R.Nakamura, A.Hirakawa, H.Watanabe, M.Ito, et al. Factors affecting longitudinal functional decline and survival in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontal Degener. 2015;16:230–6.
7. J.Mandrioli, S.Biguzzi, C.Guidi, E.Sette, E.Terlizzi, A.Ravasio,. Heterogeneity in ALSFRS-R decline and survival: a population based study in Italy. Neurol Sci. 2015. doi:10.1007/s10072-015-2343-6.
8. M.R.M.Turner, J.Scaber, J.J.Goodfellow, M.E.Lord, R.Marsden, K.Talbot The diagnostic pathway and prognosis in bulbar-onset amyotrophic lateral sclerosis. J Neurol Sci. 2010;294:81–5.
9. P.M.Andersen, P.Nilsson, M.L.Keränen, L.Forsgren, J.Hägglund, M.Karlsborg, et al. Phenotypic heterogeneity in motor neuron disease patients with Cu/Zn-superoxide dismutase mutations in Scandinavia. Brain. 1997;120 (Pt 1:1723–37).
10. J.Simón-Sánchez, E.G.P.Dopper, P.E.Cohn-Hokke, R.K.Hukema, N.Nicolaou, H.Seelaar, et al. The clinical and pathological phenotype of C9orf72 hexanucleotide repeat expansions. Brain. 2012;135:723–35.
11. R.Bowser, M.R.Turner, J.Shefner Biomarkers in amyotrophic lateral sclerosis: opportunities and limitations. Nat Rev Neurol. 2011;7:631–8.
12. V.Appel, S.S.Stewart, G.Smith, S.H.Appel A rating scale for amyotrophic lateral sclerosis: description and preliminary experience. Ann Neurol. 1987;22:328–33.
13. C.Armon, M.C.Graves, D.Moses, D.K.Forté, L.Sepulveda, S.M.Darby, et al. Linear estimates of disease progression predict survival in patients with amyotrophic lateral sclerosis. Muscle Nerve. 2000;23:874–82.
14. J.M.Cedarbaum, N.Stambler, E.Malta, C.Fuller, D.Hilt, B.Thurmond, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999;169:13–21.
15. P.H.Gordon, B.Cheng, F.Salachas, P.-F.Pradat, G.Bruneteau, P.Corcia, et al. Progression in ALS is not linear but is curvilinear. J Neurol. 2010;257:1713–17.
16. A.Chio, G.Mora, M.Leone, L.Mazzini, D.Cocito, M.T.Giordana, et al. Early symptom progression rate is related to ALS outcome: a prospective population based study. Neurology. 2002;59:99–103.
17. R.Gomeni, M.Fava Amyotrophic lateral sclerosis disease progression model. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:119–29.
18. K.Kollewe, U.Mauss, K.Krampfl, S.Petri, R.Dengler, B.Mohammadi ALSFRS-R score and its ratio: a useful predictor for ALS progression. J Neurol Sci. 2008;275:69–73.
19. F.Kimura, C.Fujimura, S.Ishida, H.Nakajima, D.Furutama, H.Uehara, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology 2006;66:265–7.
20. B.J.Traynor, H.Zhang, J.M.Shefner, D.Schoenfeld, M.E.Cudkowicz Functional outcome measures as clinical trial endpoints in ALS. Neurology. 2004;63:1933–5.
21. A.Czaplinski, A.A.Yen, S.H.Appel Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. J Neurol Neurosurg Psychiatry. 2006;77:390–2.
22. G.Bensimon, L.Lacomblez, V.Meininger, H.Iso A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994;330:585–91.
23. N.Stambler, M.Charatan, J.M.Cedarbaum Prognostic indicators of survival in ALS. ALS CNTF Treatment Study Group. Neurology. 1998;50:66–72.
24. M.M.Qureshi, D.Hayden, L.Urbinelli, K.Ferrante, K.Newhall, D.Myers, et al. Analysis of factors that modify susceptibility and rate of progression in amyotrophic lateral sclerosis (ALS). Amyotroph Lateral Scler. 2006;7:173–82.
25. N.Atassi, J.Berry, A.Shui, N.Zach, A.Sherman, E.Sinani, et al. The PRO-ACT database: design, initial analyses, and predictive features. Neurology 2014;83:1719–25.
26. L.J.Haverkamp, V.Appel, S.H.Appel Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain. 1995;118 (Pt 3:707–19).
27. P.Wicks, M.P.Massagli, C.Wolf, J.Heywood Measuring function in advanced ALS: Validation of ALSFRS-EX extension items. Eur J Neurol. 2009;16:353–9.
28. N.S.Ward, N.S.Hill Pulmonary function testing in neuromuscular disease. Clin Chest Med. 2001;22:769–81.
29. J.D.Berry, R.Miller, D.H.Moore, M.E.Cudkowicz, L.H.van den Berg, D.A.Kerr, et al. The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:162–8.
30. K.Kondo, I.Hemmi Clinical Statistics in 515 Fatal Cases of Motor Neuron Disease. Determinants of Course. Neuroepidemiology. 1984;3:139–48.
31. A.Chiò, G.Logroscino, O.Hardiman, R.Swingler, D.Mitchell, E.Beghi, et al. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. 2009;10:310–23.
32. H.Creemers, H.Grupstra, F.Nollet, L.H.van den Berg, A.Beelen Prognostic factors for the course of functional status of patients with ALS: a systematic review. J Neurol. 2014:1407–23.
33. R.Küffner, N.Zach, R.Norel, J.Hawe, D.Schoenfeld, L.Wang,. Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression. Nat Biotechnol. 2015 Jan;33(1):51–7.
34. C.T.-C.Lee, Y.-W.Chiu, K.-C.Wang, C.-S.Hwang, K.-H.Lin, I.-T.Lee, et al. Riluzole and Prognostic Factors in Amyotrophic Lateral Sclerosis Long-term and Short-term Survival: A Population Based Study of 1149 Cases in Taiwan. J Epidemiol. 2013;23:35–40.
35. P.Jennum, R.Ibsen, S.W.Pedersen, J.Kjellberg Mortality, health, social and economic consequences of amyotrophic lateral sclerosis: a controlled national study. J Neurol. 2013;260:785–93.
36. J.Labra, P.Menon, K.Byth, S.Morrison, S.Vucic Rate of disease progression: a prognostic biomarker in ALS. J Neurol Neurosurg Psychiatry. 2015:jnnp – 2015–310998. doi:10.1136/jnnp-2015-310998.
37. I.Tramacere, E.Dalla Bella, A.Chio, G.Mora, G.Filippini, G.Lauria, et al. The MITOS system predicts long-term survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2015:1–6.
38. F.Franchignoni, J.Mandrioli, A.Giordano, S.Ferro A further Rasch study confirms that ALSFRS-R does not conform to fundamental measurement requirements. Amyotroph Lateral Scler Front Degener. 2015:1–7.
39. A.Voustianiouk, G.Seidel, J.Panchal, M.Sivak, A.Czaplinski, A.Yen, et al. ALSFRS and Appel ALS scores: discordance with disease progression. Muscle Nerve. 2008;37:668–72.
40. L.H.Goldstein, S.Abrahams Changes in cognition and behaviour in amyotrophic lateral sclerosis: nature of impairment and implications for assessment. Lancet Neurol. 2013;12:368–80.
41. M.C.Mantovan, L.Baggio, G.Dalla Barba, P.Smith, E.Pegoraro, G.Soraru’, et al. Memory deficits and retrieval processes in ALS. Eur J Neurol. 2003;10:221–7.
42. J.Machts, V.Bittner, E.Kasper, C.Schuster, J.Prudlo, S.Abdulla, et al. Memory deficits in amyotrophic lateral sclerosis are not exclusively caused by executive dysfunction: a comparative neuropsychological study of amnestic mild cognitive impairment. BMC Neurosci. 2014;15:83.
43. J.C.Roche, R.Rojas-Garcia, K.M.Scott, W.Scotton, C.E.Ellis, R.Burman, et al. A proposed staging system for amyotrophic lateral sclerosis. Brain. 2012;135:847–52.
44. K.J.Felice A longitudinal study comparing thenar motor unit number estimates to other quantitative tests in patients with amyotrophic lateral sclerosis. Muscle Nerve. 1997;20:179–85.
45. S.Pinto, R.Geraldes, N.Vaz, A.Pinto, M.de Carvalho Changes of the phrenic nerve motor response in amyotrophic lateral sclerosis: longitudinal study. Clin Neurophysiol. 2009;120:2082–5.
46. J.W.Fitting, R.Paillex, L.Hirt, P.Aebischer, M.Schluep Sniff nasal pressure: a sensitive respiratory test to assess progression of amyotrophic lateral sclerosis. Ann Neurol. 1999;46:887–93.
47. R.Capozzo, V.N.Quaranta, F.Pellegrini, A.Fontana, M.Copetti, P.Carratù, et al. Sniff nasal inspiratory pressure as a prognostic factor of tracheostomy or death in amyotrophic lateral sclerosis. J Neurol. 2014;262:593–603.
48. R.A.Lyall, N.Donaldson, M.I.Polkey, P.N.Leigh, J.Moxham Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis. Brain. 2001;124:2000–13.
49. M.B.Chaudri, C.Liu, L.Watson, D.Jefferson, W.J.Kinnear Sniff nasal inspiratory pressure as a marker of respiratory function in motor neuron disease. Eur Respir J. 2000;15:539–42.
50. L.Leonardis, L.Dolenc Grošelj, G.Vidmar Factors related to respiration influencing survival and respiratory function in patients with amyotrophic lateral sclerosis: a retrospective study. Eur J Neurol. 2012;19:1518–24.
51. M.R.Turner, M.Benatar Ensuring continued progress in biomarkers for amyotrophic lateral sclerosis. Muscle Nerve. 2015, Vol 51, Issue 1, Pages 14–8. doi:10.1002/mus.24470.